Recombinant Rat Translocase of inner mitochondrial membrane domain-containing protein 1 (Timmdc1)

How is TIMMDC1 expression regulated across different tissues?

TIMMDC1 expression patterns show tissue-specific variation that corresponds to metabolic demands. Tissues with high energy requirements, such as cardiac tissue, brain, and skeletal muscle, typically demonstrate elevated TIMMDC1 expression levels compared to less metabolically active tissues. To investigate tissue-specific expression patterns, researchers employ quantitative PCR (qPCR), western blotting, and immunohistochemistry techniques. For comprehensive analysis, transcriptomic approaches like RNA-sequencing can provide tissue-specific expression profiles across multiple organs. Methodologically, comparative studies should normalize TIMMDC1 expression to established housekeeping genes while considering developmental stages and physiological states as potential variables affecting expression patterns.

What protein-protein interactions does TIMMDC1 participate in within the mitochondrial membrane?

TIMMDC1 engages in complex interaction networks within the mitochondrial inner membrane, particularly with components of the presequence translocase and complex I assembly factors. Research has identified interactions between TIMMDC1 and various Tim proteins, including the presequence receptor Tim50 and Tim21, which are involved in signal-sensitive interactions that facilitate protein import into mitochondria . To investigate these interactions, researchers utilize co-immunoprecipitation assays, proximity ligation assays, and crosslinking studies. More advanced methodologies employ techniques like BioID or APEX proximity labeling to capture transient interactions. When designing interaction studies, it's essential to preserve membrane integrity during isolation procedures to maintain native protein conformations and associations, typically using mild detergents like digitonin rather than harsher agents like SDS.

How does TIMMDC1 deficiency affect mitochondrial complex I assembly and function?

What is the pathogenic mechanism of TIMMDC1 variants in neurodegenerative disorders?

The pathogenic mechanism of TIMMDC1 variants in neurodegenerative disorders involves a complex interplay between aberrant splicing, protein deficiency, and subsequent bioenergetic failure. Research has identified a deep intronic pathogenic variant (c.597-1340A>G) that enhances aberrant splicing, resulting in almost complete loss of TIMMDC1 protein and compromised mitochondrial complex I function . This variant, present at approximately 1/5000 frequency in gnomAD, leads to an infantile-onset neurodegenerative disorder characterized by failure to thrive, poor feeding, hypotonia, peripheral neuropathy, and drug-resistant epilepsy . Mechanistically, TIMMDC1 deficiency triggers bioenergetic insufficiency in highly metabolically active neurons, with subsequent ATP depletion and oxidative stress. Additionally, there may be involvement of mitochondrial protein import clogging mechanisms, where dysfunctional proteins accumulate in translocase channels, preventing import of other essential mitochondrial proteins . To investigate these mechanisms, researchers should employ patient-derived fibroblasts or induced pluripotent stem cell (iPSC)-derived neurons for comprehensive analysis of mitochondrial function, including respirometry, ATP production, membrane potential, and complex I activity.

How might TIMMDC1 contribute to cancer progression and metastasis?

TIMMDC1 demonstrates a complex role in cancer biology, with evidence suggesting it facilitates cancer cell growth and metastasis through metabolic reprogramming and signaling pathway modulation. Research shows that TIMMDC1 expression is elevated in highly metastatic tumor cells compared to lowly metastatic ones, suggesting a potential role in cancer progression . Functionally, TIMMDC1 knockdown studies in gastric cancer cells (SGC-7901 and BGC-823) reveal significant inhibition of cell proliferation in vitro and tumor progression in vivo, with xenograft experiments showing approximately 80% reduction in tumor volume and weight following TIMMDC1 depletion . Mechanistically, TIMMDC1 appears to support cancer cells through multiple pathways: (1) maintaining mitochondrial respiration via complex I, (2) supporting glycolytic activity, and (3) promoting AKT/GSK-3β/β-catenin signaling which drives cell proliferation and survival. Experiments show that TIMMDC1 knockdown reduces phosphorylation of AKT(Ser473) and GSK-3β(Ser9), leading to decreased β-catenin and c-Myc protein levels . To study TIMMDC1 in cancer models, researchers should employ both in vitro proliferation, migration, and invasion assays, alongside in vivo xenograft and metastasis models, while monitoring both metabolic parameters and oncogenic signaling pathways.

What techniques can be used to successfully express and purify recombinant rat TIMMDC1?

Successful expression and purification of recombinant rat TIMMDC1 presents significant technical challenges due to its hydrophobic nature as a 4-pass membrane protein. A methodological approach should employ bacterial and/or eukaryotic expression systems with optimization for membrane protein production. For bacterial expression, E. coli strains like C41(DE3) or Lemo21(DE3) specifically designed for membrane proteins should be used with vectors containing solubility-enhancing tags (MBP, SUMO, or Trx). Expression conditions should be optimized at lower temperatures (16-20°C) with reduced inducer concentrations to prevent inclusion body formation. For mammalian expression, HEK293 or CHO cells may provide proper folding and post-translational modifications. Purification strategies should involve a two-step protocol: initial membrane isolation through ultracentrifugation followed by solubilization using mild detergents (DDM, LMNG, or digitonin) rather than harsh detergents that might disrupt protein structure. Affinity chromatography (using His-tag or other fusion tags) should be followed by size exclusion chromatography for optimal purity. Protein quality should be assessed through circular dichroism to confirm secondary structure integrity, while functionality can be evaluated using reconstitution into liposomes and measuring electron transport activities.

How can antisense oligonucleotides be designed and optimized for TIMMDC1 splicing correction?

Designing effective splice-switching antisense oligonucleotides (SSOs) for TIMMDC1 splicing correction requires a systematic approach focusing on sequence specificity, binding efficiency, and cellular delivery. Research has demonstrated successful SSO design for correcting the deep intronic pathogenic variant TIMMDC1 c.597-1340A>G that causes aberrant splicing . The methodological workflow should begin with comprehensive RNA analysis using RT-PCR and sequencing to characterize aberrant splicing patterns and identify critical splice regulatory elements. SSO design should target splice sites, branch points, or exonic/intronic splicing enhancers/silencers, with 15-25 nucleotide lengths for optimal specificity. Chemical modifications are crucial, with phosphorothioate backbones providing nuclease resistance and 2'-O-methyl, 2'-O-methoxyethyl, or locked nucleic acid (LNA) modifications enhancing target affinity and biological stability. Screening multiple candidate SSOs with varying lengths, positions, and modifications is essential to identify optimal performers. Delivery optimization into patient cells should compare transfection reagents (lipid-based, polyethylenimine) against naked oligonucleotide uptake. Efficacy assessment requires comprehensive analysis including RT-PCR for splicing correction, qPCR for proper transcript levels, western blotting for protein restoration, and functional assays measuring mitochondrial complex I activity and oxygen consumption rates before and after treatment.

How does TIMMDC1 interact with the presequence translocase during protein import?

Understanding TIMMDC1's interactions with the presequence translocase represents a significant research challenge requiring sophisticated experimental approaches. Evidence suggests connections between TIMMDC1 and components of the mitochondrial protein import machinery, specifically the TIM23 complex. Research has shown that the presequence translocase complex interacts with presequence-containing precursors at the intermembrane space side of the inner membrane to facilitate their translocation into the matrix . The IMS-domains of Tim50 and Tim21 interact with high affinity, approximately 10-fold greater than Tim50's affinity for presequences . When presequence docking occurs at the cis-face of the presequence translocase, it triggers internal rearrangements within the TIM23 complex, leading to Tim21 release from Tim50 . Methodologically, investigating these interactions requires sophisticated approaches such as site-specific crosslinking, FRET analysis, and reconstituted systems. Researchers should employ Cu²⁺-induced crosslinking in mitoplasts with purified proteins to capture dynamic interactions . Additional techniques include co-immunoprecipitation under various conditions (with/without presequence peptides) to detect signal-induced dissociation events, and in organello assays to observe how presequence recognition affects translocase organization . The research challenge involves capturing these transient, signal-sensitive interactions in their native environment while differentiating direct from indirect interactions.

What is the potential of TIMMDC1 as a therapeutic target in mitochondrial disease and cancer?

TIMMDC1 presents a complex dual potential as a therapeutic target, requiring distinct approaches for mitochondrial diseases versus cancer applications. For mitochondrial diseases caused by TIMMDC1 mutations, antisense oligonucleotide (SSO) therapy shows remarkable promise. Research demonstrates that SSOs can restore normal TIMMDC1 mRNA processing and protein levels in patient cells with the c.597-1340A>G variant . These SSO treatments achieve restoration of complex I subunit abundance and function, as verified through quantitative proteomics and real-time metabolic analysis . For developing this therapeutic approach, researchers must optimize oligonucleotide chemistry, delivery methods, and treatment regimens while addressing tissue-specific delivery challenges, particularly to the central nervous system. Conversely, in cancer therapy, TIMMDC1 inhibition represents the therapeutic strategy. Research shows that TIMMDC1 knockdown inhibits gastric cancer cell growth and metastasis both in vitro and in vivo through mechanisms involving reduced mitochondrial respiration, decreased glycolysis, and inactivated AKT/GSK3β/β-catenin signaling . The research challenge involves developing selective TIMMDC1 inhibitors that can target cancer cells without disrupting normal mitochondrial function in healthy tissues. Potential approaches include small molecule inhibitors, targeted degradation strategies (PROTACs), or cancer-specific delivery of TIMMDC1-targeting siRNAs. Both therapeutic directions require careful assessment of off-target effects, particularly on mitochondrial function in metabolically active tissues like heart and brain.

How does mitochondrial protein import clogging contribute to TIMMDC1-related pathologies?

Mitochondrial protein import clogging represents an emerging mechanism potentially relevant to TIMMDC1-related pathologies that requires sophisticated experimental investigation. Research has demonstrated that certain mitochondrial proteins can accumulate in translocase channels when destabilized by mutations, creating a "clog" that prevents other essential proteins from reaching mitochondria . While not directly demonstrated for TIMMDC1, this mechanism may be relevant to understanding how TIMMDC1 mutations lead to disease. Methodologically, investigating protein import clogging requires sophisticated approaches including: (1) Import kinetics assays using radiolabeled precursor proteins to detect import efficiency reductions, (2) Blue native PAGE to visualize accumulated translocase intermediates, (3) Proximity labeling techniques to identify proteins aberrantly associated with import channels, and (4) Super-resolution microscopy to visualize import channel clogging in situ. To specifically investigate if TIMMDC1 mutations cause import clogging, researchers should generate equivalent mutations in model organisms (as demonstrated with ANT1/Aac2 in yeast ), then analyze TOM and TIM complex function. Comparative proteomics between mitochondria from wild-type and mutant cells can reveal signature patterns of import deficiency. The research challenge involves distinguishing primary effects of clogging from secondary consequences of general mitochondrial dysfunction, requiring careful experimental design with appropriate controls for each mitochondrial function parameter.